PDE7B and B-cell chronic lymphocytic leukemia: Subsequently, they had found that the PDE7B mRNA level of CLL patients was 9 times higher than that of the normal control group, and the median time-to-treatment (TTT) was shortened by several years compared with the low level PDE7B mRNA16.